IL5 and Increased total eosinophil count: IL-2/JES6-1 immunocomplexes and low-dose IL-2 therapy are also stimulatory for group 2 innate lymphoid cells (ILC2s) that express CD25, which can contribute to IL-5 production and eosinophilia (24).